These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 25601637

  • 1. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S, Behler N, Irmler M, Beckers J, Friess H, Erkan M, Siveke JT, Tannapfel A, Hahn SA, Theis FJ, Esposito I, Kleeff J, Michalski CW.
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [Abstract] [Full Text] [Related]

  • 2. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N.
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [Abstract] [Full Text] [Related]

  • 3. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
    Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF.
    Cancer Res; 2015 Mar 15; 75(6):1091-101. PubMed ID: 25736685
    [Abstract] [Full Text] [Related]

  • 4. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L, Yang H, Chen K, Yuan J, Li J, Dai G, Gu M, Shi Y.
    Clin Transl Med; 2023 Dec 15; 13(12):e1500. PubMed ID: 38037549
    [Abstract] [Full Text] [Related]

  • 5. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC.
    Mol Cancer Res; 2012 Sep 15; 10(9):1228-39. PubMed ID: 22871572
    [Abstract] [Full Text] [Related]

  • 6. Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice.
    Xiong HJ, Yu HQ, Zhang J, Fang L, Wu D, Lin XT, Xie CM.
    Mil Med Res; 2023 Dec 20; 10(1):68. PubMed ID: 38124228
    [Abstract] [Full Text] [Related]

  • 7. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E.
    Mol Cancer Ther; 2015 Apr 20; 14(4):1014-23. PubMed ID: 25673820
    [Abstract] [Full Text] [Related]

  • 8. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS, Maginn EN, Gabra H, Stronach EA, Wasan HS.
    Cancer Biol Ther; 2019 Apr 20; 20(1):21-30. PubMed ID: 30261145
    [Abstract] [Full Text] [Related]

  • 9. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
    Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y.
    Oncotarget; 2017 Jul 04; 8(27):44295-44311. PubMed ID: 28574828
    [Abstract] [Full Text] [Related]

  • 10. KRAS-related proteins in pancreatic cancer.
    Mann KM, Ying H, Juan J, Jenkins NA, Copeland NG.
    Pharmacol Ther; 2016 Dec 04; 168():29-42. PubMed ID: 27595930
    [Abstract] [Full Text] [Related]

  • 11. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM, Pinto N, Khan MI, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Nichols AC.
    Oral Oncol; 2018 Sep 04; 84():95-103. PubMed ID: 30115483
    [Abstract] [Full Text] [Related]

  • 12. Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition.
    Michalopoulou E, Auciello FR, Bulusu V, Strachan D, Campbell AD, Tait-Mulder J, Karim SA, Morton JP, Sansom OJ, Kamphorst JJ.
    Cell Rep; 2020 Feb 25; 30(8):2729-2742.e4. PubMed ID: 32101748
    [Abstract] [Full Text] [Related]

  • 13. Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling.
    Luo YD, Liu XY, Fang L, Yu HQ, Zhang YJ, Chen M, Zhang LD, Xie CM.
    Theranostics; 2022 Feb 25; 12(18):7903-7919. PubMed ID: 36451866
    [Abstract] [Full Text] [Related]

  • 14. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
    Luo YD, Fang L, Yu HQ, Zhang J, Lin XT, Liu XY, Wu D, Li GX, Huang D, Zhang YJ, Chen S, Jiang Y, Shuai L, He Y, Zhang LD, Bie P, Xie CM.
    J Hepatol; 2021 Jan 25; 74(1):96-108. PubMed ID: 32738450
    [Abstract] [Full Text] [Related]

  • 15. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.
    Gastroenterology; 2015 Jun 25; 148(7):1452-65. PubMed ID: 25683115
    [Abstract] [Full Text] [Related]

  • 16. Targeting mTOR dependency in pancreatic cancer.
    Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ, Australian Pancreatic Cancer Genome Initiative (APGI), Oien KA, McKay CJ, Carter CR, Gillen G, Champion S, Pimlott SL, Anderson KI, Evans TR, Grimmond SM, Biankin AV, Sansom OJ, Morton JP.
    Gut; 2014 Sep 25; 63(9):1481-9. PubMed ID: 24717934
    [Abstract] [Full Text] [Related]

  • 17. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
    Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E.
    PLoS One; 2013 Sep 25; 8(2):e57289. PubMed ID: 23437362
    [Abstract] [Full Text] [Related]

  • 18. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC, Sancho P, Cañamero M, Martinelli P, Madriles F, Michl P, Gress T, de Pascual R, Gandia L, Guerra C, Barbacid M, Wagner M, Vieira CR, Aicher A, Real FX, Sainz B, Heeschen C.
    Gastroenterology; 2014 Nov 25; 147(5):1119-33.e4. PubMed ID: 25127677
    [Abstract] [Full Text] [Related]

  • 19. Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.
    Kong B, Cheng T, Qian C, Wu W, Steiger K, Cao J, Schlitter AM, Regel I, Raulefs S, Friess H, Erkan M, Esposito I, Kleeff J, Michalski CW.
    Mol Cancer; 2015 Dec 18; 14():212. PubMed ID: 26683340
    [Abstract] [Full Text] [Related]

  • 20. IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.
    Rajurkar M, Dang K, Fernandez-Barrena MG, Liu X, Fernandez-Zapico ME, Lewis BC, Mao J.
    Cancer Res; 2017 Jan 15; 77(2):320-329. PubMed ID: 28069799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.